111 related articles for article (PubMed ID: 31647676)
1. Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes.
Italiya KS; Basak M; Mazumdar S; Sahel DK; Shrivastava R; Chitkara D; Mittal A
Mol Pharm; 2019 Dec; 16(12):4954-4967. PubMed ID: 31647676
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat.
Italiya KS; Singh AK; Chitkara D; Mittal A
AAPS PharmSciTech; 2021 Mar; 22(3):114. PubMed ID: 33763759
[TBL] [Abstract][Full Text] [Related]
3. Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus.
Italiya KS; Mazumdar S; Sharma S; Chitkara D; Mahato RI; Mittal A
Nanomedicine; 2019 Jan; 15(1):175-187. PubMed ID: 30300750
[TBL] [Abstract][Full Text] [Related]
4. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice.
Yang Z; Chen M; Fialkow LB; Ellett JD; Wu R; Nadler JL
Pancreas; 2003 May; 26(4):e99-104. PubMed ID: 12717280
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes.
Cui P; Macdonald TL; Chen M; Nadler JL
Bioorg Med Chem Lett; 2006 Jul; 16(13):3401-5. PubMed ID: 16650991
[TBL] [Abstract][Full Text] [Related]
6. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats.
Striffler JS; Nadler JL
Metabolism; 2004 Mar; 53(3):290-6. PubMed ID: 15015139
[TBL] [Abstract][Full Text] [Related]
7. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation.
Yang Z; Chen M; Ellett JD; Fialkow LB; Carter JD; Nadler JL
Transplantation; 2004 Jan; 77(1):55-60. PubMed ID: 14724435
[TBL] [Abstract][Full Text] [Related]
8. Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism.
Chen M; Yang Z; Wu R; Nadler JL
Endocrinology; 2002 Jun; 143(6):2341-8. PubMed ID: 12021199
[TBL] [Abstract][Full Text] [Related]
9. Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans.
Świerczek A; Wyska E; Pociecha K; Baś S; Mlynarski J
Xenobiotica; 2019 Oct; 49(10):1209-1220. PubMed ID: 30526201
[TBL] [Abstract][Full Text] [Related]
10. Lisofylline: a potential lead for the treatment of diabetes.
Yang Z; Chen M; Nadler JL
Biochem Pharmacol; 2005 Jan; 69(1):1-5. PubMed ID: 15588708
[TBL] [Abstract][Full Text] [Related]
11. Inflammation blockade improves pancreatic islet function.
Yang Z; Chen M; Carter JD; Ellett JD; Smith KM; Nadler JL
Transplant Proc; 2004 Nov; 36(9):2864-5. PubMed ID: 15621169
[TBL] [Abstract][Full Text] [Related]
12. Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery.
Danquah M; Fujiwara T; Mahato RI
Biomaterials; 2010 Mar; 31(8):2358-70. PubMed ID: 20018369
[TBL] [Abstract][Full Text] [Related]
13. Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1 beta-induced dysfunction in cultured rat islets.
Bleich D; Chen S; Bursten SL; Nadler JL
Endocrinology; 1996 Nov; 137(11):4871-7. PubMed ID: 8895359
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat.
Italiya KS; Sharma S; Kothari I; Chitkara D; Mittal A
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():49-56. PubMed ID: 28704725
[TBL] [Abstract][Full Text] [Related]
15. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice.
Yang ZD; Chen M; Wu R; McDuffie M; Nadler JL
Diabetologia; 2002 Sep; 45(9):1307-14. PubMed ID: 12242464
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice.
Wyska E; Świerczek A; Pociecha K; Przejczowska-Pomierny K
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):403-12. PubMed ID: 25663650
[TBL] [Abstract][Full Text] [Related]
17. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline.
Bright JJ; Du C; Coon M; Sriram S; Klaus SJ
J Immunol; 1998 Dec; 161(12):7015-22. PubMed ID: 9862738
[TBL] [Abstract][Full Text] [Related]
18. Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice.
Clarke E; Rice GC; Weeks RS; Jenkins N; Nelson R; Bianco JA; Singer JW
Cancer Res; 1996 Jan; 56(1):105-12. PubMed ID: 8548748
[TBL] [Abstract][Full Text] [Related]
19. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling.
Coon ME; Diegel M; Leshinsky N; Klaus SJ
J Immunol; 1999 Dec; 163(12):6567-74. PubMed ID: 10586050
[TBL] [Abstract][Full Text] [Related]
20. Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids.
Bursten SL; Federighi D; Wald J; Meengs B; Spickler W; Nudelman E
J Pharmacol Exp Ther; 1998 Jan; 284(1):337-45. PubMed ID: 9435196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
